MiNK Therapeutics, Inc. (INKT)

Market Cap	57.67M
Revenue (ttm)	n/a
Net Income (ttm)	-11.27M
Shares Out	4.52M
EPS (ttm)	-2.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,480
Open	13.00
Previous Close	13.22
Day's Range	12.40 - 13.12
52-Week Range	4.56 - 76.00
Beta	0.33
Analysts	Buy
Price Target	37.50 (+194.12%)
Earnings Date	Nov 14, 2025

About INKT

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients wi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT
• Website: https://minktherapeutics.com

Analyst Summary

According to 3 analysts, the average rating for INKT stock is "Buy." The 12-month stock price target is $37.5, which is an increase of 194.12% from the latest price.

Price Target

$37.5

(194.12% upside)

Analyst Consensus: Buy